On August 20, 2025, Rhythm Pharmaceuticals announced that the FDA accepted its supplemental New Drug Application for setmelanotide in acquired hypothalamic obesity, granting the submission Priority ...

HF Sinclair announced in August 2025 that it will redeem all of its outstanding 5.875% and 6.375% senior notes due 2026 and 2027, including notes issued by its subsidiaries, following the completion ...